This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klugman, K. P. Articles by Bryskier, A. Search for Related Content PubMed PubMed Citation Articles by Klugman, K. P. Articles by Bryskier, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Dec 1996, 2802-2804, Vol 40, No. 12
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time- kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin

KP Klugman, T Capper and A Bryskier
MRC/SAIMR/WITS Pneumococcal Diseases Research Unit, Department of Medical Microbiology, South African Institute for Medical Research, Johannsburg, South Africa. 174klug@chiron.wits.ac.za

Among 180 clinical isolates of pneumococci, no strains were found to be resistant to levofloxacin (MIC, > or = 4 micrograms/ml) whereas 9% were resistant to ofloxacin and 7% were resistant to ciprofloxacin. Synergism was demonstrated by time-kill studies in nine of nine strains for the combination of levofloxacin and vancomycin and in six of nine strains for levofloxacin plus teicoplanin. The combinations of levofloxacin with rifampin or fusidic acid were indifferent. Resistant mutants could be selected using incremental concentrations of levofloxacin. For two of nine strains that were initially susceptible to levofloxacin, the MICs reached the resistance range (> or = 4 micrograms/ml). In contrast, ciprofloxacin and ofloxacin selected mutants from the susceptible to the resistant range more frequently (four of six and six of seven strains, respectively). These data argue for further study of levofloxacin against penicillin-resistant pneumococci.

This article has been cited by other articles:

• Brian, S. R., Kimbrough, R. C. III (2004). Salvage of a Prosthetic Knee Joint Infected with Resistant Pneumococcus. A Case Report. JBJS 86: 2302-2304 [Full Text]  
• Heffelfinger, J. D., Dowell, S. F., Jorgensen, J. H., Klugman, K. P., Mabry, L. R., Musher, D. M., Plouffe, J. F., Rakowsky, A., Schuchat, A., Whitney, C. G., and the Drug-Resistant Streptococcus pneumoniae Th, (2000). Management of Community-Acquired Pneumonia in the Era of Pneumococcal Resistance: A Report From the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 160: 1399-1408 [Abstract] [Full Text]  
• Legg, J. M., Bint, A. J. (1999). Will pneumococci put quinolones in their place?. J Antimicrob Chemother 44: 425-427 [Full Text]  
• Fitoussi, F., Doit, C., Geslin, P., Bingen, E. (1999). Killing Activities of Trovafloxacin Alone and in Combination with beta -Lactam Agents, Rifampin, or Vancomycin against Streptococcus pneumoniae Isolates with Various Susceptibilities to Extended-Spectrum Cephalosporins at Concentrations Clinically Achievable in Cerebrospinal Fluid. Antimicrob. Agents Chemother. 43: 2372-2375 [Abstract] [Full Text]